Edition:
India

Atossa Genetics Inc (ATOS.OQ)

ATOS.OQ on NASDAQ Stock Exchange Capital Market

2.08USD
20 Sep 2019
Change (% chg)

-- (--)
Prev Close
$2.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,093
52-wk High
$7.39
52-wk Low
$0.81

Latest Key Developments (Source: Significant Developments)

Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet
Thursday, 11 Jul 2019 

July 11 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS ANNOUNCES NEW PROPRIETARY MODIFIED-RELEASE ORAL ENDOXIFEN TABLET; PHASE 1 CLINICAL TRIAL INITIATED.ATOSSA GENETICS INC - ATOSSA HAS COMMENCED A PHASE 1 STUDY IN AUSTRALIA TO ASCERTAIN PHARMACOKINETICS OF TABLET.ATOSSA GENETICS INC - DEVELOPING A NEW PROPRIETARY MODIFIED-RELEASE ORAL TABLET FORM OF ITS ENDOXIFEN.  Full Article

Atossa Genetics Announces "Expanded Access" FDA Approval Of Endoxifen For 1 Patient
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS ANNOUNCES FDA APPROVAL OF ENDOXIFEN FOR “EXPANDED ACCESS” AS PREOPERATIVE SYSTEMIC ENDOCRINE THERAPY FOR A U.S. BREAST CANCER PATIENT.  Full Article

Atossa Genetics Qtrly Loss Per Share $2.90
Tuesday, 14 Aug 2018 

Aug 13 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.ATOSSA GENETICS INC QTRLY LOSS PER SHARE $2.90.  Full Article

Atossa Genetics Receives Positive Interim Review From Independent Safety Committee In Phase 1 Topical Endoxifen Dose Escalation Study In Men
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS RECEIVES POSITIVE INTERIM REVIEW FROM INDEPENDENT SAFETY COMMITTEE IN PHASE 1 TOPICAL ENDOXIFEN DOSE ESCALATION STUDY IN MEN.ATOSSA GENETICS - INDEPENDENT SAFETY COMMITTEE REVIEWED BLINDED DATA FROM FIRST GROUP IN STUDY, CONCLUDED STUDY MAY ADVANCE TO NEXT DOSING LEVEL.  Full Article

Atossa Genetics posts Q3 loss per share ‍$0.18​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Atossa Genetics Inc :Atossa Genetics announces third quarter 2017 financial results and provides company update.Atossa Genetics Inc qtrly loss per share ‍$0.18​.  Full Article

L1 Capital Global Opportunities Master Fund reports 9.01 pct passive stake in ‍atossa Genetics, as of Oct. 26
Saturday, 4 Nov 2017 

Nov 3 (Reuters) - L1 Capital Global Opportunities Master Fund Ltd: :L1 capital global opportunities master fund ltd reports 9.01% passive stake in ‍atossa genetics inc, as of october 26, 2017 - SEC filing‍​.  Full Article

Empery Asset Management reports 9.01 pct passive stake in Atossa Genetics
Wednesday, 1 Nov 2017 

Oct 31 (Reuters) - Empery Asset Management LP::Empery Asset Management LP reports 9.01 percent passive stake in Atossa Genetics as of Oct 26 - SEC filing‍​.  Full Article

Atossa Genetics announces pricing of $5.1 million public offering
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Atossa Genetics Inc :Atossa Genetics announces pricing of $5.1 million public offering of common stock.Says public offering of 11.5 million common shares priced at $0.44per share.  Full Article

Atossa Genetics announces proposed public offering of common stock
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Atossa Genetics Inc ::Atossa Genetics announces proposed public offering of common stock.Says ‍intends to offer and sell shares of its common stock in an underwritten public offering​.  Full Article